Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The more you dig into this , the more it looks like they are just using SAGA to get news out, maybe drum up interest and buy time for Africa progress to gain momentum. I just can't see how any of the BP Enzolytics are said to be working with wouldn't jump at a 450m deal to own the technology as far as we have been told about the SAGA deal implies. That price is a drop in the bucket for them, and they would have no issues leaving the current managemment in place to oversee ( run the two companies ) and would most likely pay them alot more than they current salaries are. Most likely they would even go a billion for the two companies and wouldn't blink an eye.
Something is going on that is alot bigger than this so called SAGA deal. To spend two years on lawsuits ( that if you are going to sell it really wouldn't have matter other than being personal because the shares were already accounted for they were in the O/S ) , audits , just to say we are selling the 2 companies we formed to protect future lawsuits from the past, and oh Enzolytics won't have assets but will continue on the OTC .IMO
Again it is a wait and see game at this point. We will see how long it takes to get this off the ground in Africa. We have been hearing about Africa for years now even though they never stated a date they sure made it sound like it was around the corner rather than 2 years away. It will also be interesting to see if ENZC has another .10-.13 run and how many will sell off and then hope it doesn't take off and instead drops again to buy in again. IMO GLTA
Sagaliam Acquisition Corp. is a blank check company that was incorporated on March 31, 2021 for the purpose of effecting a merger or similar business combination with one or more businesses. As of July 28, 2023, Sagaliam has not completed any mergers yet, but it has announced a non-binding term sheet for the purchase of Biogenysis Inc. and Virogentics Inc., operating subsidiaries of Enzolytics Inc., for $450,000,000. The deadline for this transaction is April 23, 2023. Sagaliam also had a previous deal with Arabian Entertainment Group, but it collapsed in March 6 2023.
Nasdaq Listing Rule 5250 (c) (1) requires Nasdaq-listed corporations to submit to the SEC on a timely basis all periodic financial reports required, such as Forms 10-K, 10-Q, and 8-K1. The rule mandates compliance with Rule 5250 (c) (1) as a condition of continuous listing. Nasdaq provided companies 60 days to submit a plan detailing how they intended to regain compliance with Nasdaq’s listing rules regarding timely filings.
So first they were going to be delisted due to value , now they don't report on time, as the above statement says been in business for almost 2.5 years and have not completed any mergers ( that means they are not making anymoney for over 2 years and still might have a million dollar penalty for the Arabian deal where will that money come from ). Very interesting that they have a SP of 10+ dollars and Enzolytics has everything from cures, products being sold, A/I platform, and has a SP of .042. The more you dig into this company it is a mess. It really sounds like they need Enzolytics more than Enzolytics needs them. IMO
Also a post or two from me shows almost 20% of investors pulled out last QRT.
I thought we were leaving all the crazy dealings in the past, or is Harry working the deals again? IMO not bashing just looking at the DD if someone can provide anything that disproves what is currently out there about the company please post. GLTA is an understatement
Who really knows what is going on behind the curtain , shareholders dont. have a great weekend . GLTA
I have tried to find where Sagaliam has completed a deal , so far no luck. It seems all their PR's state they have secured funding ect and then nothing happens and they kick the can down the road.
Not that I use this as a guide or anything it was just a link that was provide when researching has SAGA finalized a deal. It seems the CEO has two companies he running that are investment related both show no dealings completed. Not bashing oneway or the other, just showing what comes up when trying to find a deal that has been successful completed
look up Barry M Kostiner
https://www.aaii.com/investingideas/article/23143-is-sagaliam-acquisition-corp-saga-stock-a-good-investment
Here is a PR from them show the sixth extension this is what I copied from the first time
, very weird
https://finance.yahoo.com/news/sagaliam-acquisition-corp-confirms-funding-052000513.html
I see that this shows one thing and what I copied shows another thing both coming from SAGA . Weird this is from your link look at this section . So once again are we looking at errors or copy and paste butcher jobs . Their are two Business Combination Extension, yours comes from page 2 and mine comes from page 4 same link you provided. What are we missing ? I can't believe they are working two different deals with the same time line. Was this the sale to BN Holdings that was completed june 26 they are talking about.
Business Combination Extension
The date by which the Company has to complete its business combination has been extended by the Company from June 23, 2023 to July 23, 2023 (the “Extension”) by depositing $57,380.22 into the trust account for its public stockholders. The Extension is the seventh of ten one-month extensions permitted under the Company’s governing documents and provides the Company with additional time to complete its business combination.
Completion of Sale of Membership Interests in Sagaliam Sponsor, LLC
Maybe true , but the SAGA extensions were happening before Enzolytics was in the picture, go back and look at the failed venture with Arabian entertainment deal. Timelines they are searching to put a deal together with little time they have left. Not going to argue with you about SAGA and why or why not the extensions are needed clearly Enzolytics was not their first choice for the SPAC and time is running out. GLTA
https://news.spacconference.com/2022/11/29/sagaliam-acquisition-asks-shareholders-for-up-to-10-more-months-on-arabian-entertainment-deal/
Expect another extension update to be released today
Yes it is a real company , private setup. I have not been able to find who the trustee are form in Nevada . The one in India is a different company. Their is a shipping company out of Australia also. Try your luck finding out who is behind them.
https://www.marketscreener.com/quote/stock/SAGALIAM-ACQUISITION-CORP-133224976/news/Sagaliam-Acquisition-Corp-NasdaqGM-SAGA-executed-a-non-binding-term-sheet-to-acquire-Biogenysis-43529737/
this is interesting to read
https://www.marketscreener.com/quote/stock/SAGALIAM-ACQUISITION-CORP-133224976/news/Sagaliam-Acquisition-Corp-Auditor-Raises-Going-Concern-Doubt-44000742/
https://www.reuters.com/legal/us-securities-regulator-hits-top-spac-auditor-with-10-mln-fine-2023-06-21/
Reading this May made six , June would have made 7, July would be 8th , Aug makes 9 , Sept would be 10 and would have to be completed by Oct 23rd
Business Combination Extension
The date by which the Company has to complete its business combination has been extended by the Company from May 23, 2023 to June 23, 2023 (the “Extension”) by depositing $57,380.22 into the trust account for its public stockholders. The Extension is the sixth of ten one-month extensions permitted under the Company’s governing documents and provides the Company with additional time to complete its business combination.
Here is what MP posted awhile back about Z Trust
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171091788
BM the first part of your post is correct , the question of BN Holdings it is not the same. BN Holding Trust is what you are looking for which is a private setup trust, I have been trying look up information on it and their is nothing out there I can find. I would say they will extend tomorrow they have been filing extensions around the 29th of the month by way of 8k. Its just a sit and wait as normal. GLTA
https://www.globenewswire.com/news-release/2023/06/29/2697280/0/en/SAGALIAM-ACQUISITION-CORP-CONFIRMS-FUNDING-AND-EXTENSION-OF-DEADLINE-TO-COMPLETE-BUSINESS-COMBINATION.html
Yes I recall when you did that. Something is behind the ENZC curtain. One key element would be if we see the management team doing something with their shares if they are not converting or selling they have something up their sleeves and over 600M reason they are not. IMO GLTA
One thing not to rule out is the mysteries Regeneron drug that has that ability to neutralize viruses. They have said they were starting trials in the later part of 2023 which we are in. Regeneron also delivers sooner that they predict not like Enzolytics. Just maybe that is what Enzolytics has in their back pocket. Remember ITV-1 is not a cure and Clone 3 was promoted to investors as one. The silence on Clone 3 might because Enzolytics has done enough on it and is letting Regeneron bring it to the finish line under their dime and if proven out a exclusive licensing deal is done. IMO GLTA
The ratio as they gave example would be 100,000 @ 900 shares @ 10.00 , but still a good buy . GLTA
Did anyone else see this from yesterday
King of Prussia
@ImKingofPrussia
$ENZC "IPF IMMUNE" TRADEMARK APPROVED FOR PUBLICATION!
$ENZC "IPF IMMUNE" TRADEMARK APPROVED FOR PUBLICATION! 🔥 https://t.co/gAGQIq4ZnU pic.twitter.com/2pT142BMlF
— King of Prussia (@ImKingofPrussia) July 24, 2023
BM I think alot of longs might selloff half of holdings @ anything over .75, as for the 5 dollar level I know I would take the 20M and be totally out. GLTA
Cat a little confused
IMO I think when CC stated ENZC will have no assets, many maybe reading that as if Enzolytics has an actual product they are giving away in the SAGA deal. Enzolytics doesn't have a product they are exclusively lincensed to build on the technology that is in the trust. Asset as define ( property owned by a person or company, regarded as having value and available to meet debts, commitments, or legacies:) Meaning without seeing the fine print of the SAGA deal the leasing will still be going thru Enzolytics. The need to be off the OTC really wouldn't be needed to sign contracts and collect a royalty. Maybe that is why the directors of Enzolytics are not worried about their 600+M shares, also keep in mind that all their contracts expire this year. So either they renew with Enzolytics or they enter a new one with SAGA which if money isn't holding the deal up it could be contracts for them. Just throw it out there again IMO with no details it is all a guess. GLTA
Not sure about the personal timeline, it was more that Enzolytics missed their own timelines and made everything in 2020-2021 to be as if it was right around the corner ( meaning a few months not the 2 years and counting that it has turn into ) Ex Chandra post, CC audits uplistings facts are facts and they made the statements not the shareholders. Not crying just holding and waiting IMO GLTA
With this as a post Chandra is stating how the patents are held and works. Even though it is not on the Enzolytics website as news or as some say fact as one of the directors of a public traded company if the statement is incorrect that would be grounds for action which we know thoses patents are in the trust. Not all the patents are in the trust, hopefully they are under Enzolytics and that is what they are planning on doing licence to the two subsidiaries if deal goes thru or whoever else comes knocking.
The other strange thing is I didn't see mention in the PR today about the SAGA deal. I would think that it would be a good place to mention that the company is under negotiations with SAGA to become a new Bio Company under the future name of XYZ. Publicity is a good thing especially if you are in negotiations trying to get the best deal. IMO
As the ball bounces we will stay tuned as I just look at SP great news and it is down GLTA
Yes either waiting to see Africa midway data, then they all can decide how much it is really worth to them and maybe then we know who all is under NDA's. Regeneron should be close to starting whatever they were going to be doing at the later part of the year that they stated.
The next few months should be telling one way or the other.GLTA
Just thinking out loud
If the SAGA deal like we have been lead to believe is close , would the investors that are backing this 450M deal in SAGA be buying up shares of ENZC . To me if I am one of the investors who is involved in putting this deal together and it is close I would be buying ENZC shares right now like crazy. Meaning if I am involved in part of that 450M , I surely have a few extra millions sitting around to buy the stock I am going to be getting a dividend of sum sort.
ex 3 million would buy approx 65,217,391.30434783 shares , if it wasn't a good deal why would I be part of a 450M deal. So if there are say 10 people or groups that are investing to make up the 450M, think about the amount of people who would know and have deep pockets to buy ENZC shares at .045 even if it wasn't for millions of dollars each volume should be more than what is currently happening. IMO
Our volume isn't showing really anything different from our past volume when it trades in .044-.048 range a few million a day.
Either they don't have the investors yet, or this was a way of generating interest as some of the patents filings were anticipated over the next couple of months along with the Africa trials getting started and news closer to the end of year from there. Since it is a non bidding deal as mentioned that might be the loophole that keeps from breaking any SEC rules. All just thinking aloud. GLTA
This thinking might be caused from being on a mower for two hours in the Va. heat,
No problem it is hard to keep up with the bouncing ball Enzolytics .
When looking into alot of it they are building on past filings of JC which is good because alot of the research has already been proven and issued. Like they have been saying building on 40 years of research GLTA
Yes the two are older , I was refering to the most recent ones that were filed , sorry for the confusion
Here is what I was making referecing
Application PCT/US2022/016926 events
Priority claimed from US202163152084P
2022-02-18
Application filed by Cotropia Joseph, Gaurav Chandra
2022-08-25
Publication of WO2022178216A2
2022-09-29
Publication of WO2022178216A3
Here is another example of Enzolytics holding the technology and giving rights to the subsidiary companies, Below is the statement from , the link points out what they want out of patents. The bottom three paragraphs are the key. IMO this is what Enzolytics will hold.
The Company's wholly owned subsidiary Biogenysis, Inc. holds the exclusive license to this technology and manages this technology field for the Company.
Enzolytics, Inc.
April 4, 2023·7 min read
Enzolytics, Inc.
In this article:
ENZC
-1.18%
Watchlist
Watchlist
COLLEGE STATION, TX / ACCESSWIRE / April 4, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).
Enzolytics today announced progress on its ongoing program to produce Monoclonal Antibodies to treat animals by filing a comprehensive patent application covering its identification of conserved neutralizable epitopes on the Feline Leukemia (FeLV) virus. Using the Company's Artificial Intelligence technology, more than 26 immutable epitope sites on the FeLV virus have been identified. These sites are claimed in the filed patent application. The patent covers the use of any of its discovered numerous conserved Feline Leukemia epitopes in the production of monoclonal antibodies, the production of vaccines, or use in diagnostic tests for detecting the virus in cats. The Company's wholly owned subsidiary Biogenysis, Inc. holds the exclusive license to this technology and manages this technology field for the Company.
While the Company's focus is on producing monoclonal antibodies for treating numerous human viruses, including COVID-19, HIV, HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA), the Company has also analyzed epitopes of animal viruses, namely the Cat Feline Leukemia Virus (FeLV), Horse Equine Infectious Anemia Virus, Chicken Anemia Virus, Koala Retrovirus (KoRV), Elephant Endotheliotropic Herpes Virus (EEHV), Avian Flu Swine Flu, This analysis has revealed the conserved immutable sites on these viruses against which monoclonal antibody production is planned. The findings will ultimately be claimed in U.S. and foreign patent applications.
Targeting the conserved sites discovered by Enzolytics allows the production of a therapeutic that will not be rendered ineffective due to mutation (variants) of the virus. Even a "variant form of the virus" will contain the immutable targeted sites. Targeting immutable sites avoids the ineffectiveness that is experienced when a therapeutics or vaccine targets a site that has mutated.
Currently, there is no cure for Cat Feline Leukemia (FeLV) virus. The cost of treatment of the virus is significant. There are more than 45 million cats in the U.S. and over 25% of households in America own one or more cats. FeLV is one of the most common infectious diseases in cats. This virus affects a significant percentage of the cat population in the United States, resulting in millions of cats suffering from it. This same problem exists around the world in the world population of 600 million cats.
Production of monoclonal antibodies targeting this animal virus and bringing this therapy to market will be more direct and the time to treatment of animals will be significantly less than is the case required for monoclonal antibodies developed for the treatment of individuals. The Company has initiated discussions with animal health providers who express an interest in this technology and its end product.
The production of these monoclonal antibodies begins in the Company's lab located at the Texas A&M University Institute for Preclinical Studies [https://tips.tamu.edu/]. The lab uses the Company's proprietary methodology for producing fully species-specific monoclonal antibodies which target conserved, immutable sites on the viruses, thereby avoiding ineffectiveness due to virus mutation.
The methodology implemented by the Company to produce monoclonal antibodies is proprietary and the subject of the Company's pending international patent applications. In the initial process step, Artificial Intelligence (AI - computer analysis) is used to identify conserved, immutable epitopes on the target virus utilizing Enzolytics' proprietary AI platform. In the AI initial analysis process step, the sequences (structure) of virus isolates are analyzed. From that analysis, epitopes (target sites) are identified which are conserved across all isolates curated. The Company production process is then employed to produce monoclonal antibodies targeting these identified conserved sites.
As a part of this process, 3 Dimensional models of these conserved targets are generated, and the targets may be analyzed for linearity, accessibility by antibodies, and neutralizability by antibodies. Then Enzolytics produces multiple broadly neutralizing antibodies targeting these multiple conserved, immutable epitopes on the targeted virus.
Enzolytics' methodology for producing monoclonal antibodies is unique and innovative, unlike those employed by other biotech companies. In the case of a monoclonal antibody to treat an animal virus, the Company's antibodies are produced from animal "immune-B cells", obtained from convalescent animals who have recovered from the target virus. The Company's monoclonal antibodies are then developed directly where the original antibody affinity and specificity are maintained, and the chances of immunogenicity are minimized.
Enzolytics' Focus on Intellectual Property (IP)
"As Enzolytics advances its science and clinical products, the Company continues to build a robust Intellectual Property portfolio", said Gaurav Chandra, MD, the Company COO. "Intellectual property protection is crucial to fostering innovation. Our focus is on gaining competitive advantage through an aggressive patent strategy."
Charles Cotropia, the Company CEO, said, "The patent system is an optimum way for a small biotech company to lay claim, for a 20-year period dating back to an early priority date, to significant intellectual property even before or without bringing the therapeutic to market. The filing of a patent application serves as a constructive reduction to practice of the subject matter described in the application. In this way, we are taking every opportunity to cover the waterfront on all the viruses we are analyzing."
The breadth of patent coverage that is sought and expected is extremely far-reaching based on the discovery of the critical target epitope sites necessary to neutralize these viruses most effectively. The Company has identified conserved epitopes using its AI platform on multiple viruses in addition to HIV and COVID-19, namely HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA). The same has been accomplished in multiple animal viruses. These findings will be the subject of protection through international patents. Patent coverage can be expected covering the discovered conserved epitopes for these human and animal viruses, and additionally on the use of any of the discovered epitopes/antigens in producing therapies, any vaccines or related prophylactic/therapeutic method relating to the identified epitope/antigens and on diagnostics. Our patent portfolio will be extensive."
Enzolytics PCT application fillings I was referencing a few post back are coming up basically on 14-16 months now, so we should be seeing updates on them at anytime. Items are still protected under the filings, so making it to the last step is a great thing. IMO
When making to this stage and filing is what will start moving the deals forward. The animal side was hyped and a very range of treatment was displayed to us and has been very silent lately , watch for this to be the next area invovling deals. Animals trials alot quickier by standars requirements. The Feline leukemia virus treatment was one they were speaking about alot and working with an animal BP. IMO GLTA
https://finance.yahoo.com/news/enzolytics-announces-progress-development-patenting-110000381.html
Remember back when they got opinions back on the application filings that is basically when they would have started filing, if they had the fees ect. to do so.
26) What happens to my application in the national phase?
Once you have entered the national phase, the national or regional patent Offices concerned begin the process of determining whether they will grant you a patent. Any examination which these Offices may undertake should be made easier by the PCT international search report and the written opinion and even more by an international preliminary examination report.
At bottom of 10
Since, in the national phase, each patent Office is responsible for examining your application in accordance with national or regional patent laws, regulations and practices, the time required for the examination and grant of a patent varies across patent Offices.
Nice catch , I was just looking at some filings and ran across that , looking into the patents that they put applications in for I dont see a company but members of the Enzolytics team who are listed as filed by. I provided the links below the click on the PCT # and see what you find. Maybe I missed it . With how Enzolytics has it listed on their website they application filings are for the methodology of the tech. GLTA
https://enzolytics.com/enzolytics-inc-intellectual-property/
https://www.biospace.com/article/releases/enzolytics-inc-announces-u-s-distribution-of-ipf-immune-tm-and-progress-in-each-of-its-therapeutic-platforms/
I believe you are looking for this .
https://www.wipo.int/pct/en/faqs/faqs.html
Here is a Pr from 2022 describing all the Patents they have applications currently filed for. I can not find the list with who actually filed. The write up only mentions the company Enzolytics not the sub companies. Leading one to believe it was under Enzolytics which if true they would have the licensing rights. They may not hold the asset as a dosage or pill form as we are looking at ex ITV1, but hold the protocol and procedures of how it is created, a recipe you could call it. GLTA
https://patentgc.com/patent-application-process/#:~:text=1%20A%20PCT%20application%20is%20filed%20with%20a,the%20patentability%20of%20the%20PCT%20application%E2%80%99s%20subject%20matter.
Just DD GLTA
https://www.marketscreener.com/quote/stock/ENZOLYTICS-INC-120792338/news/Enzolytics-Highlights-Its-Comprehensive-PCT-Patent-Applications-Covering-Discovered-Conserved-Targ-39862907/#:~:text=In%20submissions%20under%20the%20Patent%20Cooperation%20Treaty%20%28PCT%29%2C,diagnostic%20tests%20for%20detecting%20the%20viruses%20in%20patients.
How is your project coming along
Sorry I must have missed it , but they haven't started the trial yet. If so can you please show the PR stating they have started. I agree it would be nice to hear something positive in the trial but that is months off. GLTA
MP just asking because I honesty don't know , what you are describing would that be insider trading? Not that rules are to be broken and goverment offical have done it for years.
This all could be a PIPE dream and nothing goes thru and by then we have the Africa news and we move up. Again why hasn't one of the partners stepped up that should be the 450m question? IMO Held this long whats a few more months, hahhaa
Wouldn't SAGA have to hold the money in sometype of escrow to have the value of the company be 450m so the shares they give to ENZC ( shareholders) have the 10 dollar value?
I understand what your saying , I guess we could say that about our management team too. IMO
I guess what I find a little weird is Samsung, Twist , Intel or any of the other big boys ENZC have mentioned working with after seeing the deal SAGA is trying to do. Not a single one of our partners said hey we will buy the two companies from you and set you up as a NASDAQ spinoff company under our ownership and will leave your management team in tact that we know of. Any of them have the money and means to do so. IMO
I would think with the details they offered us 450m, making whole provisions ect they would have changed it to a bidding agreement instead of a non bidding agreement as far as we know it. IMO GLTA